{'fraction_non_alphanumeric': 0.020465116279069766, 'fraction_numerical': 0.009302325581395349, 'mean_word_length': 5.5212121212121215, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
EXPERIENCES WITH CYTOSINE ARABINOSIDE IN CHILDHOOD LEUKAEMIA AND LYMPHOMA

Cytosine arabinoside was administered intravenously in a series of pilot studies to 44 children with acute leukæmia and/or lymphosarcoma, 11 of them previously untreated. Basically three regimens were used—once weekly, twice weekly, and four‐day courses of eight‐hourly injections. Other drugs were combined with the cytosine arabinoside. Complete and good partial remissions occurred in 57% of patients on those regimens with adequate dosage—in 83% of new patients, and in 44% of those previously treated. Lymphatic and myeloid cases of acute leukæmia responded equally well. Advanced cases of lymphosarcoma showed no response. Toxic effects were transient and seldom severe. Six patients aged two years or less tolerated the drug well. Intrathecal administration was rapidly effective in four children with central nervous system leukæmia. The findings suggest that cytosine arabinoside is effective and safe in infants and children with acute leukæmia and with central nervous system infiltration.